Optum AI Market Strategy Report - ED Treatment Pills

Answer Capsule

Optum holds minimal recommendation power in the ED treatment pills category, with valid recommendation coverage of just 0.66% in September 2026. The brand appears in only 2.30% of qualified observations, and its presence has declined significantly since July 2026, when coverage stood at 3.10%. Optum's clearest weakness is near-total absence from AI-generated shortlists, while its strongest signal is a small pocket of positive framing where the brand does appear. The clearest opportunity lies in rebuilding basic recommendation eligibility before pursuing higher placement positions.

Who This Report Is For

This report is for brand, digital strategy, and market intelligence leaders at Optum evaluating how AI-driven discovery is shaping provider selection in the ED treatment category.

Report Card

Executive Summary

Optum's position in the ED treatment pills category is defined by near-invisibility rather than negative framing. The benchmark shows Optum present in just 2.30% of qualified observations in September 2026, with valid recommendation coverage of 0.66%. This places Optum at the bottom of the tracked set alongside K Health, and far behind category leaders Hims at 46.56% and Ro at 45.90%.

The trend is moving in the wrong direction. Optum's valid recommendation coverage declined from 3.10% in July 2026 to 0.66% in September 2026, a 2.4 percentage point drop classified as beyond normal variation for the series. The brand's mention presence also contracted, falling from roughly 21.2% in July to 2.30% in September, indicating Optum is being named less often, not just recommended less.

Optum recorded no negative mentions in the September set. Its 7 mentions split between 4 positive and 3 neutral observations, producing a net sentiment score of 0.5714. The brand's strongest platform signal appears in Google AI Mode, where Optum registered its only rank-eligible recommendation. Its clearest gap is structural: Optum is absent from most AI-generated shortlists entirely, and it holds no rank-one recommendations on any tracked platform.

What Optum Is Winning

Optum's wins are narrow but identifiable. The brand recorded zero negative mentions across all 305 qualified observations in September 2026, meaning that when AI systems reference Optum, the framing is not cautionary or critical.

Optum also shows a small pocket of positive visibility in Google AI Mode, where it registered 1 valid recommendation with an average recommended rank of 3.0. This is the only platform where Optum achieved rank-eligible recommendation status, and it suggests at least one prompt cluster surfaces Optum as a viable option.

The brand's net sentiment score of 0.5714, while the lowest among the top eight tracked brands, remains positive. For a brand with minimal presence, the absence of negative framing is a foundation to build on rather than a weakness to repair.

Where Optum Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is Optum being filtered out before AI-generated shortlists are formed?
• How does Optum's presence and recommendation conversion compare with category leaders?
• On which platforms does Optum appear only as a neutral mention or not at all?

Optum's primary gap is recommendation eligibility itself. The brand appears in only 7 of 305 qualified observations, and of those, just 2 qualify as valid recommendations. This means Optum is being filtered out early in the AI answer-generation process, before shortlists are formed.

The contrast with category leaders is stark. Hims appears in 91.15% of observations and converts 46.56% into valid recommendations. Ro appears in 85.90% and converts 45.90%. Optum's presence rate of 2.30% is roughly 40 times lower than the leaders, and its recommendation conversion is proportionally weaker.

Optum holds no rank-one recommendations on any platform. Its only top-three appearance is a single observation in Google AI Mode. On ChatGPT, Copilot, Gemini, Perplexity, and AI Overviews, Optum either appears as a neutral mention or does not appear at all. The brand is not competing for first-position placement; it is struggling to enter the consideration set.

The decline pattern is also concerning. Optum's coverage fell from 3.10% in July to 0.66% in September, a significant drop on a small base. Its mention presence roughly halved over the same period. The evidence suggests Optum's already minimal footprint is contracting, not stabilizing.

Biggest Opportunity

Questions This Section Answers

• What is the priority for moving Optum's valid recommendation coverage toward mid-tier benchmark levels?
• Which evidence layer must Optum build to enter AI-generated shortlists consistently?

Optum's clearest opportunity is rebuilding basic recommendation eligibility in the brand recommendation cluster that dominates this category. All 305 qualified observations in September 2026 fell into the brand recommendation class, which captures prompts where users seek a specific treatment provider.

Optum does not need to win rank-one placement immediately. The priority is moving from 0.66% valid recommendation coverage toward the 7.21% level held by Blink Health or the 10.49% held by BlueChew. That requires Optum to appear in AI-generated shortlists consistently, which in turn requires the public evidence layer to support Optum as a legitimate option for ED treatment.

The path runs through the source footprint: clinical, pharmacy, and telehealth pages that AI systems can retrieve and synthesize when answering discovery prompts. Optum's existing positive framing provides a base, but the brand needs more retrievable sources that position it as a recommended provider rather than a passing reference.

Competitive Landscape

Questions This Section Answers

• Which brands hold dominant recommendation-stage strength in the ED treatment pills category?
• Where does Optum rank relative to the rest of the tracked set on key recommendation metrics?

Hims and Ro hold dominant recommendation-stage strength in the ED treatment pills category, with GoodRx Care emerging as a strong third. Optum sits at the bottom of the tracked set, competing with K Health for last position rather than challenging the leaders.

Average recommended rank covers rank-eligible recommendations only.

The table shows Optum tied with K Health for the lowest top-three rate in the category and holding no rank-one recommendations. Optum's single rank-eligible recommendation carries an average rank of 3.0, but the sample is too small to indicate meaningful placement strength.

Prompt Evidence

Google AI Mode / Brand Recommendation Prompt: "What is the best online pharmacy?" Result: Optum appeared once as a rank-eligible recommendation, its only top-three placement in the September set.

Gemini / Brand Recommendation Prompt: "Can a Teladoc prescribe Cialis?" Result: Optum was mentioned once in a neutral context with no recommendation credit, illustrating presence without shortlist entry.

Copilot / Brand Recommendation Prompt: "best online pharmacy" Result: Optum appeared as a single positive mention but received no valid recommendation, showing the gap between being named and being chosen.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map which prompt clusters and AI surfaces are producing Optum's few mentions and where competitors are displacing the brand.

Phase 2: Recommendation Readiness Plan Identify the minimum evidence layer needed for Optum to enter AI-generated shortlists consistently in the brand recommendation cluster.

Phase 3: Owned Answer Layer Buildout Develop Optum-owned pages that directly answer discovery prompts for ED treatment, online prescriptions, and telehealth options.

Phase 4: Citation / Authority Layer Development Strengthen the third-party source footprint that AI systems can retrieve, focusing on clinical and pharmacy authority signals.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track whether Optum's presence rate and valid recommendation coverage are moving toward the mid-tier benchmark levels.

Why This Matters

Questions This Section Answers

• What does Optum's 0.66% valid recommendation coverage mean for buyer discovery?
• Why is absence from AI-generated shortlists decisive for Optum?

When a buyer asks an AI system which ED treatment provider to use, Optum is rarely part of the answer. The brand's 0.66% valid recommendation coverage means that in roughly 99 of every 100 qualified discovery prompts, AI systems do not recommend Optum at all.

Presence alone is not enough, but absence is decisive. Optum cannot win recommendations it never enters. The next move is not chasing rank-one placement; it is building the retrievable evidence layer that gets Optum onto the shortlist in the first place.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Optum, this equals (4 × 1 + 3 × 0 + 0 × -1) / 7, producing a score of 0.5714.

This matters because unclassified mention counts are misleading. Optum's 7 mentions look similar to K Health's 7 mentions at first glance, but Optum's sentiment score of 0.5714 is meaningfully higher than K Health's 0.4286. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, neutral reference, cautionary mention, and competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Optum's AI visibility and recommendation performance in the ED treatment pills category, not a client implementation case study.
2. The reporting window is September 2026, with trend comparisons drawn against July 2026 and August 2026 baseline measurements.
3. Six canonical AI platform families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The analysis is based on 305 qualified observations in September 2026, drawn from a raw collection of 800 prompt-surface observations.
5. The competitor universe includes 10 tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, PlushCare, BlueChew, Blink Health, Rex MD, K Health, and Optum.
6. All qualified observations in the September series fell into the brand recommendation cluster, which captures discovery and consideration prompts seeking a specific treatment provider.
7. Stage 0 extraction captured prompt-level data including query, AI surface, answer, brand outcome, recommendation placement, sentiment, and citations where exposed.
8. A mention is defined as any appearance of Optum in a qualified observation, regardless of whether the brand was recommended.
9. A valid recommendation is defined as an appearance in which Optum is actively recommended or shortlisted, distinct from a neutral reference or passing mention.
10. Limitations: Optum's small mention count (7) and valid recommendation count (2) mean individual observations carry outsized weight. Percentage movements should be interpreted with this limited base in mind. The public benchmark records change but does not establish causality. Source presence is evidence about the information environment, not proof that a source caused a recommendation outcome.

See How AI Is Recommending Your Brand

The public benchmark shows where Optum stands, but company-level analysis reveals which prompts matter most, which competitors take the recommendation when Optum loses, and which external sources shape those answers. A focused AI visibility audit maps those patterns into a prioritized strategy for moving from 0.66% coverage toward meaningful shortlist presence.